Prenetics Global (PRE) Insider Cheng Yin Pan Buys 15,873 Shares
Recent internal trades at Prenetics Global Limited highlight activity among key personnel as the consumer health firm draws fresh Wall Street attention.
Reviewed by automated data checks against the source filing. How we make and check alerts
Cheng Yin Pan bought 15,873 shares of Prenetics Global Limited ($PRE) on June 15, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $PRE is down 3.8% after 1 week, down 5.6% after 1 month and down 10.8% to date (from the $20.75 close on Jun 15, 2026).
PRE
Prenetics Global Limited
Key Points
- Prenetics Global Limited insider Cheng Yin Pan acquired 15,873 shares on June 15, 2026, alongside other internal transactions.
- Shares of PRE traded around $20.51 on Wednesday, sitting within a 52-week price span ranging from $11.37 to $27.24.
- Wall Street firms have actively covered the consumer health company, keeping a strong buy consensus and high price targets.
Get $PRE trade alerts by text
We text you when insiders, Congress or big funds trade $PRE. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Prenetics Global Limited alert may contain errors. Disclosures
Insider Buying and Selling at Prenetics Global Limited
On June 15, 2026, insider activity at Prenetics Global Limited (NasdaqGM: PRE) brought fresh attention to the consumer health sciences firm. Filings show that Cheng Yin Pan picked up 15,873 shares on that date. Additional internal transactions occurred on the same day, including activity from David Vanderveen, who also bought and sold shares as part of a busy period of insider movements.
Stock Performance and Recent Trading
Shares of PRE traded around $20.51 on Wednesday. The company's stock has swung between a 52-week low of $11.37 and a peak of $27.24 over the past year. The 50-day moving average sits at $21.34, while the 200-day moving average rests near $18.92. Market participants continue to monitor these price levels as internal stakeholders adjust their holdings.
Wall Street Analyst Coverage
Wall Street firms have kept a close eye on the company through a series of recent notes. On October 12, 2026, Lucid Capital Markets initiated coverage with a buy rating and a $54.00 price target. Craig-Hallum started coverage with a buy rating and a $40.00 target on September 17, 2026, while B. Riley Securities initiated coverage with a buy rating and a $37.00 price target on August 27, 2026. Benchmark also maintained its buy rating on July 15, 2026, raising its target to $40.00 from $30.00.
Inside the Business Operations
Prenetics Global Limited operates as a consumer health sciences company focusing on human health and longevity through science-backed products under the IM8 brand. It also runs a consumer genetic testing brand in CircleDNA, leveraging sequencing technology to deliver personalized reports. Founded in 2014, the company operates across the United States and Hong Kong from its headquarters in Quarry Bay, Hong Kong.
What to Watch at Prenetics Global Limited
Investors will look toward the company's next earnings report scheduled for November 10, 2026, for further clues on revenue growth and profitability. Additional SEC filings will also track whether insiders continue adjusting their positions through the remainder of the year.
Related Filing Alerts
Source: Cheng Yin Pan's Form 4 filing on $PRE (Jun 15, 2026). Find the original filing: PRE Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts